



**OncoDNA**<sup>®</sup>  
THE CANCER THERANOSTIC COMPANY

## International User Group Meeting

22<sup>nd</sup> / April 2026  
Valencia / Spain

PD. Dr. Marcel Trautmann  
Gerhard-Domagk-Institute of Pathology  
- Translational & Molecular Pathology Dx -  
University Hospital Münster (UKM)

Comprehensive Genomic Profiling  
(OncoDEEP) identifies potential  
**therapeutic targets and reveals  
novel insights** into the genomic  
landscape of **extraskelletal myxoid  
chondrosarcoma**

# NGS platform


## - Molecular / Genomics Dx -

- 2023 ● **NGS Automation System & NovaSeq**  
(Beckman Coulter Biomek i7)
- 2022 ● **Comprehensive genomic profiling / OncoDEEP (>1Mb)**  
(HRD, MSI, TMB, 638 genes SNV/InDel/CNV)
- 2019 ● **TruSight Oncology 500 & PierianDx**
- 2018 ● **MiniSeq (Illumina)**  
Division of Translational Pathology  
Prof. Dr. Wolfgang Hartmann
- 2015 ● **MiSeq & NextSeq500 (Illumina)**



# NGS-based clinical Dx testing

## - Panels -



**> First Department of Pathology in Germany and the first member within the German Network for Personalized Medicine (DNPM) to implement OncoDNA's OncoDEEP kit solution in our routine pan-cancer genomic/molecular Dx NGS workflow for in-house CGP**

**Pathology-directed reflex testing**

Cholangiocarcinoma / CCC

Colorectal cancer / CRC

Endometrial carcinoma

Non-small-cell lung cancer / NSCLC

Ovarian cancer

Prostate cancer


**>400x  
library prep**

**>3,350  
samples**


**Ø 2-3x NGS  
run / week**

**<3%  
failed QC  
(low input)**


- SARCOMAGENESIS / What is so special? -



Myxoid liposarcoma  
(MLS)



Synovial sarcoma  
(SySa)



Extraskeletal myxoid  
chondrosarcoma  
(EMC)

# 1. It's **RARE.**

Only **1%** of all **adult cancers**

Breast

Lung

Prostate

**Sarcoma**

**20%** of all **childhood cancers**


**Incidence**

**7 cases / 100.000**

**6.000 / year** 

# - KEY FACTS ABOUT **SARCOMA** -

## 2. Can **ARISE** from a **VARIATEY** of tissues.



**85 % Soft tissue**



**15 % Bone**

Angiosarcoma  
Dermatofibrosarcoma  
Epithelioid sarcoma  
Ewing's sarcoma  
Fibrosarcoma  
Gastrointestinal stromal tumors

**150+**  
Subtypes

## 3. Therapeutic options are **LIMITED** due to...

> genetic heterogeneity



advanced or metastatic **STS 16%**




Genomic profiling  
Genetic biomarkers  
Sarcoma subtyping


> **Molecular based precision therapy**




# - Extraskelatal myxoid chondrosarcoma / EMC -



**EWSR1::NR4A3**




# - Objectives -




# - EMC patient cohort -

## Extraskelletal myxoid chondrosarcoma (n=76)


Gender




Age



Tumor size



Tumor cell content




Analysis

**CGP & Gene fusion**




CGP

Gene fusion

only



## CGP QC / OncoDEEP DNA panel (OncoDNA)






## Enabling clinical data-driven decision

Over the past decade, there has been a rapid acceleration in the innovation of cancer diagnostics, treatments, and patient management. As a result of this acceleration, a tremendous amount of data is now generated. When this data is interconnected, it has the potential to provide oncology experts such as laboratory, Pharma company or academics with a comprehensive insight, enabling data-driven decision-making.

**Gregori Ghitti**  
[g.ghitti@oncodna.com](mailto:g.ghitti@oncodna.com)



[Request a demo](#)



# #KTA



- **Extraskelletal myxoid chondrosarcomas (EMC)** are rare mesenchymal neoplasms, accompanied by high rates of recurrence and metastases.
- The molecular hallmarks of EMCs are cytogenetic *NR4A3* rearrangements, generating chimeric **NR4A3 fusion oncoproteins**.
- **Genomic landscape of EMC – Comprehensive genomic profile / OncoDEEP:**
  - >1,700 variants have been identified in 69 tissue specimens:
    - **48% of pts with novel pathogenic or likely pathogenic variants**

**> novel therapeutic actionability with potential clinical benefits identified by CGP via in-house OncoDEEP kit**

PD. Dr. Marcel Trautmann  
**Gerhard-Domagk-Institute of Pathology**  
- Translational & Molecular Pathology Dx -  
University Hospital Münster (UKM)  
marcel.Trautmann@ukmuenster.de

